Amynas

Founded in 2019 in Antwerp, Belgium, Amynas' mission is to reduce implant-related infections - leading to reduced hospital re-admission rates for post-surgical complications. Its lead candidate product is a fully bioresorbable envelope made of millions of drug-coated immunomodulatory electrospun nanofibers specifically designed to promote healthy tissue growth around the implant (anti-inflammatory and anti-scarring) and reduce the infection rate - all while avoiding conventional antibiotics confronted with rising resistance rates. To conduct the high-level research needed to develop this new technology, Amynas is teaming up with several academic and private partners. Surrounded by the best and driven by an unmet medical need, Amynas aims to truly make a difference for patients with implantable devices.

• Employees4